Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.
Inclusion Criteria:
Exclusion Criteria:
Boston, Massachusetts 02114, United States
Pittsburgh, Pennsylvania 15213, United States
Wenatchee, Washington 98801, United States
Bogot, Cundinamarca 0000, Colombia
Kecskemét, 6000, Hungary
Shinjyuku-ku, Tokyo, Japan
Szczecin, 70-111, Poland
Wroclaw, 50-368, Poland
Simferopol, Autonomous Republic of Crimea 95006, Ukraine